The latest biotech news

health awareness day week month calendar

News and Trends 24 Nov 2022

New Labiotech Health Awareness Days listings page

Earlier this year, we added a page to the website with all of the global events and conferences taking place. It’s been very well received, and we’ve had plenty of messages telling us of events to add. Now, we’ve added a new resource to our site. It’s a list of all of the health and […]

November 24, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

BIA and Exopharm sign joint research agreement to develop integrated technology

Slovenian-based Sartorius BIA Separations (BIA), a bio-chromatography company, and Australia’s Exopharm Ltd., a company working with transformative medicines using exosomes, or extracellular vesicles (EVs), have entered into a formal collaboration. A material transfer agreement has been signed by both companies and an associated collaborative program has been implemented which aims to exploit the synergy of […]

November 23, 2022 - 4 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

Significant therapeutic potential of OSE Immunotherapeutics’ CLEC-1 published

OSE Immunotherapeutics SA has announced the publication of data in the peer-reviewed journal Science Advances on a first-in-class preclinical program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy. The academic collaboration conducted with Elise Chiffoleau’s team at the Center for Translational Research in Transplantation and Immunology has led to identify CLEC-1 as […]

November 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

Concern as study says new covid sub-variant is resistant to all therapeutic antibodies

All approved antibody therapies for Covid-19 are ineffective against the Omicron sub-lineage BQ.1.1. That’s the worrying news following a recent study by researchers at the German Primate Center (DPZ) – Leibniz Institute for Primate Research and Friedrich-Alexander University Erlangen-Nürnberg. Omicron sub-variant BQ.1.1 is currently on the rise worldwide. As a result of an infection with […]

November 23, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

Khondrion’s mitochondrial diseases treatment producing positive results

Clinical-stage pharmaceutical company, Khondrion, discovering and developing therapies targeting primary mitochondrial diseases announced yesterday (November 22) its wholly-owned lead asset sonlicromanol for MELAS spectrum disorder has demonstrated positive treatment results. MELAS spectrum disorder is a rare progressive mitochondrial disease and sonlicromanol will move into a phase 3 registrational study supported by favorable benefit-risk profile. The […]

November 23, 2022 - 5 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

UCB publishes Lennox-Gastaut syndrome study data

UCB has announced the publication of long-term open-label extension (OLE) study results of FINTEPLA (fenfluramine) CIV in the journal Epilepsia. Long-term efficacy and safety findings showed that FINTEPLA, when added to a patient’s current anti-epileptic treatment regimen for seizures associated with Lennox-Gastaut syndrome (LGS), was effective in reducing the frequency of multiple seizure types and […]

November 23, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

Funding to develop wearable patch for type 2 diabetes

A project to develop a patch worn on the cheek that delivers peptide treatments for type 2 diabetes has been awarded just under €3.8 million ($3.9 million) by the EU’s Horizon Europe RESILIENCE program. The ‘BUCCAL-PEP’ project will combine skills to develop a multifunctional biomaterial patch which allows, for the first time, delivery of peptide […]

November 23, 2022 - 4 minutesmins - By Jim Cornall

cardiology cardiovascular disease heart attack

News and Trends 23 Nov 2022

Trial to start for new heart attack drug

A potential new drug to improve the long-term outcomes for heart attack patients will be trialed in the U.K. With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the U.K.: the Queen Elizabeth Hospital, Birmingham […]

November 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

Immune cells in ALS patients can predict the course of the disease

By measuring immune cells in the cerebrospinal fluid when diagnosing ALS, it is possible to predict how fast the disease may progress. This according to a study from Karolinska Institutet in Sweden, which has been published in Nature Communications. ALS is a rare, but fatal, disease that affects the nerve cells and leads to paralysis […]

November 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma

An impressive crowd gathered at Chiesi Pharmaceutical Group yesterday (November 21) to mark the much-anticipated start of work at its Biotech Center of Excellence, bringing the future of medicine to Parma. Guests, which included Vice Minister of Business and Made in Italy, Valentino Valentini, joined to celebrate the start of the work on the building, […]

November 23, 2022 - 5 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

First patients dosed with Infex Therapeutics’ RESP-X for chronic respiratory disease

A new anti-virulence therapy, RESP-X, treating Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients has been given to the first subjects in a trial run by Infex Therapeutics. Infex Therapeutics is an anti-infectives company and announced the first subjects were dosed in the phase 1 study in healthy volunteers evaluating the company’s lead […]

November 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

Tevogen Bio to investigate T cell therapy in long Covid

Tevogen Bio is set to study the potential therapeutic use of its investigational Covid-19 T cell therapy, TVGN-489, in long Covid. The finding that none of the patients in the TVGN 489 proof-of-concept (POC) trial, treated for their initial Covid infection, developed long Covid to date is leading Tevogen to explore the potential of TVGN […]

November 23, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

New Labiotech Health Awareness Days listings page

BIA and Exopharm sign joint research agreement to develop integrated technology

Significant therapeutic potential of OSE Immunotherapeutics’ CLEC-1 published

Concern as study says new covid sub-variant is resistant to all therapeutic antibodies

Khondrion’s mitochondrial diseases treatment producing positive results

UCB publishes Lennox-Gastaut syndrome study data

Funding to develop wearable patch for type 2 diabetes

Trial to start for new heart attack drug

Immune cells in ALS patients can predict the course of the disease

Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma

First patients dosed with Infex Therapeutics’ RESP-X for chronic respiratory disease

Tevogen Bio to investigate T cell therapy in long Covid

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!